Potential of imatinib mesylate as a novel treatment for pulmonary fibrosis

2008 ◽  
Vol 2 (4) ◽  
pp. 419-431
Author(s):  
Mantej Chhina ◽  
Oksana A Shlobin ◽  
Geraldine Grant ◽  
Steven D Nathan
2019 ◽  
Vol 53 (2) ◽  
pp. 1801699 ◽  
Author(s):  
Coralynn Sack ◽  
Ganesh Raghu

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease of unknown origin that is associated with high morbidity and mortality. In this perspective, we briefly review the current understanding of the pathophysiology of IPF and the importance of environmental triggers as a precipitant of disease. We discuss occult intrinsic and extrinsic environmental factors that affect the lung microenvironment and may contribute to the development and progression of disease. The clinical implications of this framework need to be further elucidated, because prompt identification and elimination of occult exposures may represent a novel treatment modality.


2005 ◽  
Vol 85 (1) ◽  
pp. 1-16 ◽  
Author(s):  
Antonia M. S. Müller ◽  
Uwe M. Martens ◽  
Silke C. Hofmann ◽  
Leena Bruckner-Tuderman ◽  
Roland Mertelsmann ◽  
...  

2021 ◽  
Vol 57 (1) ◽  
pp. 247-259
Author(s):  
Afaf Hendawy Kamel ◽  
Eman Adel Hassanin Sherif ◽  
Waleed Khaled. El Zawawy ◽  
Nashwa Ahmed El-shinawy

CHEST Journal ◽  
2018 ◽  
Vol 154 (4) ◽  
pp. 461A
Author(s):  
VINAY GOSWAMY ◽  
IGNACIO PORTALES CASTILLO ◽  
SUMON ROY ◽  
HARINDER SINGH ◽  
LAURIE LERNER

2008 ◽  
Vol 58 (8) ◽  
pp. 2538-2542 ◽  
Author(s):  
Jörg H. W. Distler ◽  
Bernhard Manger ◽  
Bernd M. Spriewald ◽  
Georg Schett ◽  
Oliver Distler

Respiration ◽  
2008 ◽  
Vol 75 (3) ◽  
pp. 350-354 ◽  
Author(s):  
Hideaki Yamasawa ◽  
Yukihiko Sugiyama ◽  
Masashi Bando ◽  
Shoji Ohno

2019 ◽  
Vol 19 (3) ◽  
pp. 95-102
Author(s):  
Adamcakova Jana ◽  
Palova Romana ◽  
Mokra Daniela

Abstract Pulmonary fibrosis, represented mainly by idiopathic pulmonary fibrosis, develops chronic and progressive changes in lung parenchyma with high mortality and limited therapeutic options. The aim of this review was to summarize the most common experimental models used in the research of pulmonary fibrosis. Lung damage associated with development of pulmonary fibrosis can be caused by irradiation or by instillation of bleomycin, fluorescein isothiocyanate (FITC), silicon dioxide (silica), asbestos, etc. This article reviews the characteristics of the most frequently used animal models of fibrosis, including the limitations of their use. Although none of the used animal models resembles completely the changes in human pulmonary fibrosis, similarities between them allow preclinical testing of novel treatment approaches or their combinations in the laboratory conditions before their use in the clinical practice.


Sign in / Sign up

Export Citation Format

Share Document